Cargando…

Gemcitabine-induced skin necrosis

Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus...

Descripción completa

Detalles Bibliográficos
Autores principales: Haydock, Maria Monica, Sigdel, Saroj, Pacioles, Toni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207959/
https://www.ncbi.nlm.nih.gov/pubmed/30397477
http://dx.doi.org/10.1177/2050313X18809268
_version_ 1783366620331114496
author Haydock, Maria Monica
Sigdel, Saroj
Pacioles, Toni
author_facet Haydock, Maria Monica
Sigdel, Saroj
Pacioles, Toni
author_sort Haydock, Maria Monica
collection PubMed
description Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar–plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported. In our report, we present a 74-year-old male with adenocarcinoma of the pancreas, status-post pancreaticoduodenectomy (Whipple procedure), who developed a rare case of skin necrosis of the lower leg 2 weeks after completing six cycles of monotherapy gemcitabine treatment.
format Online
Article
Text
id pubmed-6207959
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-62079592018-11-05 Gemcitabine-induced skin necrosis Haydock, Maria Monica Sigdel, Saroj Pacioles, Toni SAGE Open Med Case Rep Case Report Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar–plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported. In our report, we present a 74-year-old male with adenocarcinoma of the pancreas, status-post pancreaticoduodenectomy (Whipple procedure), who developed a rare case of skin necrosis of the lower leg 2 weeks after completing six cycles of monotherapy gemcitabine treatment. SAGE Publications 2018-10-30 /pmc/articles/PMC6207959/ /pubmed/30397477 http://dx.doi.org/10.1177/2050313X18809268 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Haydock, Maria Monica
Sigdel, Saroj
Pacioles, Toni
Gemcitabine-induced skin necrosis
title Gemcitabine-induced skin necrosis
title_full Gemcitabine-induced skin necrosis
title_fullStr Gemcitabine-induced skin necrosis
title_full_unstemmed Gemcitabine-induced skin necrosis
title_short Gemcitabine-induced skin necrosis
title_sort gemcitabine-induced skin necrosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207959/
https://www.ncbi.nlm.nih.gov/pubmed/30397477
http://dx.doi.org/10.1177/2050313X18809268
work_keys_str_mv AT haydockmariamonica gemcitabineinducedskinnecrosis
AT sigdelsaroj gemcitabineinducedskinnecrosis
AT paciolestoni gemcitabineinducedskinnecrosis